Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Method Development and Validation

<- Back to I. Materials Science Vol. 9 Iss. 2

Cite the paper

Balaji Jayagopal, Murugesh Shivashankar (2017). Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Method Development and ValidationMechanics, Materials Science & Engineering, Vol 9. doi:10.2412/mmse.96.97.276

Authors: Balaji Jayagopal, Murugesh Shivashankar

ABSTRACT. The apprehension and criticism on the quality and reliability of pharmaceutical products has augmented substantially, ensuing the regulatory bodies avowing the necessity of systematic principles for drug development. ICH instituted series of guidelines such as Q8, Q9, Q10 and Q11, all accentuating on implementation of systematic approaches of Quality by design (QBD) and Process Analytical Techniques (PAT). Quality by design has earned plentiful civility by formulation developers, the approach with sound scientific knowledge and early risk assessment is been accepted as an integral and imperative part of dosage form development, relishing the benefits of risk assessments on early stage and design space on the latter stage of product life cycle. However, the idea, reference, guidance and convention of practicing QBD in analytical discipline is limited, this article pronounces the ideologies and methodology of practising analytical QBD (AQBD) in analytical method development, dissolution test development and stability testing and validation design. The milestones of QBD such as Critical material attributes (CMA), Quality target product profile (QTPP), Critical quality attributes (CQA), Critical method parameters (CMP) and guidance for effective Design of experiments (DOE) differing from the conventional one factor at a time (OFAT) methodology are well explained. The software resources available for designing and interpretation of experiments, the statistical outcomes, its significance in establishing the control strategy and design space are well explained.

Keywords: AQbD, CMA, CQA, DOE, CMM, QBD.

DOI 10.2412/mmse.96.97.276


[1] Abboud, L., & Hensley, S. (2003). New prescription for drug makers: Update the plants. The Wall Street Journal. 3-9.

[2] Juran, J.M. (2002). Product Inspection Guides. Retrieved from Skymark website:

[3] Juran, J., & Blanton, A. G. (1999). Juran’s Quality Handbook. NY: McGraw Hill.

[4] Juran, J.M. (1992). Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services. NY: The Free Press.

[5] Early, J. F. (2013, February 14). Quality by Design, Part 1. Quality Digest. Retrieved from Qualitydigest website:

[6] Bhupinder, S.B. (2014). Quality by Design (QbD) for Holistic Pharma Excellence and Regulatory Compliance. Pharma Times, 46(08), 26-33.

[7] Department of Health and Human Services USFDA. (2007). Pharmaceutical Quality for the 21st century A risk-based approach progress report. Retrieved from FDA website:

[8] Vogt, F.G., & Kord, A.S. (2011). Development of Quality-By-Design Analytical methods. Journal of Pharmaceutical sciences, 100(3), 797-812.

[9] Department of Health and Human Services USFDA. (2004). Pharmaceutical CGMPs for the 21st century – A risk-based approach Final report. Retrieved from FDA website:

[10] Department of Health and Human Services USFDA, CDER, CVM, ORA. (2004). Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Retrieved from FDA website:

[11] Sangshetti, J.N., Deshpande, M., Zaheer, Z., Shinde, D.B., & Arote, R. (2014). Quality by design approach: Regulatory need. Arabian Journal of Chemistry. Retrieved from sciencedirect website:

[12] Peraman, R., Bhadraya, K., & Yiragamreddy, P.R. (2015). Analytical Quality by Design: A Tool for Regulatory Flexibility and Robust Analytics. International Journal of Analytical Chemistry, 2015. Retrieved from hindawi website:

[13] ASME. B89.7.3.1-2001. (2001). Guidelines for decision rules: considering measurement uncertainty in determining conformance to specifications.

[14] Eurachem. (2007). Use of uncertainty information in compliance assessment. Retrieved from eurachem website:

[15] Beg, S., Sharma, G., Katare, O.P., Lohan, S., & Singh, B. (2015). Development and Validation of a Stability-Indicating Liquid Chromatographic Method for Estimating Olmesartan Medoxomil Using Quality by Design. Journal of Chromatographic Science, 53(7), 1048-1059.

[16] Rozet, E., Lebrun, P., Michiels, J.F., Sondag, P., Scherder, T., & Boulanger, B. (2015). Analytical Procedure Validation and the Quality by Design Paradigm. Journal of Pharmaceutical statistics, 25(2), 260-268.

[17] Karmar, S., Garber, R., Genchanok, Y., George, S., Yang, X., & Hammond, R. (2011). Quality by Design (QbD) based development of a Stability Indicating HPLC Method for Drug and Impurities. Journal of chromatographic science. 49(6), 439-446.

[18] Karmarkar, S., Miller, R., Yang, X., & Garber, R. (2009). Design of Forced Degradation Experiments to Demonstrate Specificity of Stability Indicating Methods for Pharmaceutical Injection Products. Presented at the LC-GC Pham Sep Conference. Philadelphia, PA.

[19] International Conference on Harmonisation (ICH) Tripartite Guideline. (August 2009). ICH Q8(R2).

[20] Gohel, M.C., Sarvaiya, K.G., Shah, A.R., & Brahmbhatt, B.K. (2009). Mathematical Approach for the Assessment of Similarity Factor using a New scheme for Calculating Weight. Indian Journal of Pharmaceutical Sciences, 71(2), 142-144.

[21] Li, Y., Terfloth, G.J., & Kord, A.S. (2009). A Systematic approach to RP-HPLC method development in a pharmaceutical QbD environment. Americal Pharmaceutical review, 12, 87-95.

[22] International Conference on Harmonisation (ICH) Tripartite Guideline. (November 2005). ICH Q9.

[23] Kumamoto, H., & Henley, E. (1996). Probabilistic risk assessment and management for engineers and scientists. (2nd ed.). Piscataway, NJ: IEEE Press.

[24] Ishikawa, K. (1985). What is total quality control? The Japanese way. Englewood Cliffs, NJ: Prentice-Hall, pp 63–64.

[25] Raman, N.V.V.S.S., Mallu, U.R., & Bapatu, H.R. (2015). Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing. Journal of Chemistry, 2015.

[26] Thomas, A.L. (2014). Design of Experiments for Analytical Method Development and Validation. BioPharm International, 27(3). Retrieved from Biopharm International website:

[27] Roy, R. K. (2001). Design of Experiments Using the Taguchi Approach : 16 Steps to Product and Process Improvement. Bk&Cd-Rom edition. John Wiley & Sons.

[28] Giunta, A. A., Wojtkiewicz, S.F., & Eldred, S. M. Overview of modern Design of experiments for computational simulations. American Institute of Aeronautics and Astronautics. Retrieved from research gate website:

[29] Control Strategy Case Studies. Retrieved from ICH website: Web Site/Training/GCG – Endorsed Training Events/APEC LSIF JCCT workshop Beijing China Dec 08/Day 2/Control Strategy Case Studies.pdf.

[30] Drug product and delivery, SSCI, Crystallization Expert. (2014). Retrieved from ssci-inc website:

Creative Commons Licence
Mechanics, Materials Science & Engineering Journal by Magnolithe GmbH is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at